Regeneron Eyes 2 New Ophthalmology Treatments

After watching sales of its macular degeneration drug Eylea take off toward blockbuster status, biopharmaceuticals specialist Regeneron Pharmaceuticals (NASDAQ: REGN  ) is eying new opportunities and bought the full rights to two novel ophthalmology programs it's been developing with Sanofi (NYSE: SNY  ) .

Regeneron announced today that it will pay Sanofi $20 million upfront for the antibodies that target receptors for platelet-derived growth factor (PDGF), the angiopoietin2 (ANG2) receptor, and ligands for ophthalmological ailments. There is the potential for Sanofi to earn an additional $45 million in development milestone payments and sales royalties.

Sanofi will receive $10 million each for the PDGF and ANG2 therapies and could earn as much as $40 million more on the former and an additional $5 million on the latter.

Regeneron had originally developed the two programs, but had included Sanofi in its antibody collaboration under which Sanofi will continue to work on developing ANG2 on uses outside of ophthalmology. That will further include ANG2 antibody REGN910 that is currently in phase 1 development in patients with advanced cancer.

In February Regeneron reported that fourth-quarter earnings tripled as sales of Eylea jumped to $276 million. Sanofi owns 17% of Regeneron but cannot own more than 30% of the biopharmaceutical.

link


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2407450, ~/Articles/ArticleHandler.aspx, 9/18/2014 8:13:25 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement